Hi Kareem
I think you should already have access, but try this link too:
https://eu.jotform.com/build/251844061659361?iak=b119c4bf50eb323820b9e7b1e3c93ec4-54ebba036de6c775
Best
Michael
From: thorsten hamann via Soc25 <soc25@biobrillouin.org>
Sent: Tuesday 9 September 2025 14:09
To: soc25@biobrillouin.org
Subject: [Soc25] Re: FW: [EXTERN] FW: [Info] Abstract Submission for 9th International BioBrillouin Meeting (Berlin, 25-27 Nov 2025) open!!!
|
[External Email] This email originated outside of Trinity College Dublin.
Do not click links or open attachments unless you recognise the sender and know the content is safe.
|
Hi there,
I think we should be pragmatic about this.....
Thorsten
On 09/09/2025 12:04, Kareem Elsayad via Soc25 wrote:
Hi All,
Seems mid Oct abstract confirmation might be bit late for some people to plan travel (see below).
Would you be ok to make exceptions and send early “approval” emails to some before (after we all review said abstract and agree) -- or else I would tell him to wait until Oct 14th?. I don’t see any harm in making such exceptions as long as we unanimously agree on case per case basis that we want said abstract as talk.
@Michael is there a way that we can also have access to submitted abstracts?
All the best,
Kareem
From: "Larin, Kirill" <klarin@Central.UH.EDU>
Date: Tuesday, 9. September 2025 at 05:26
To: Kareem Elsayad <kareem.elsayad@meduniwien.ac.at>
Subject: [EXTERN] FW: [Info] Abstract Submission for 9th International BioBrillouin Meeting (Berlin, 25-27 Nov 2025) open!!!
Dear Kareem:
My collaborator from MDACC needs an official acceptance email in order to begin making travel arrangements. Do you know when the decisions will be communicated?
Thank you for your help!
Warmly,
Kirill
From: Sokolov,Konstantin <ksokolov@mdanderson.org>
Sent: Monday, September 8, 2025 10:18 PM
To: Larin, Kirill <klarin@Central.UH.EDU>
Subject: RE: [Info] Abstract Submission for 9th International BioBrillouin Meeting (Berlin, 25-27 Nov 2025) open!!!
Hi Kirill,
I submitted my abstract. However, I can start doing my travel arrangements only after I receive an official email with an acceptance for an oral presentation. So, it would be great if it can be “accelerated” 😊
Thanks!
Kostia.
From: Larin, Kirill <klarin@Central.UH.EDU>
Sent: Sunday, August 31, 2025 2:42 PM
To: Sokolov,Konstantin <ksokolov@mdanderson.org>
Subject: [EXTERNAL] FW: [Info] Abstract Submission for 9th International BioBrillouin Meeting (Berlin, 25-27 Nov 2025) open!!!
SLOW DOWN! - EXTERNAL SENDER: klarin@Central.UH.EDU
Be suspicious of tone, urgency, and formatting. Do not click/open links or attachments on a mobile device. Wait until you are at a computer to confirm you are absolutely certain it is a trusted source.
If you are at all uncertain use the Report Phish button and our Cybersecurity team will investigate.
From: Giuliano Scarcelli <scarc@umd.edu>
Sent: Sunday, August 31, 2025 2:40 PM
To: Larin, Kirill <klarin@Central.UH.EDU>
Subject: Fwd: [Info] Abstract Submission for 9th International BioBrillouin Meeting (Berlin, 25-27 Nov 2025) open!!!
---------- Forwarded message ---------
From: Kareem Elsayad <kareem.elsayad@meduniwien.ac.at>
Date: Sat, Aug 9, 2025 at 7:57 PM
Subject: [Info] Abstract Submission for 9th International BioBrillouin Meeting (Berlin, 25-27 Nov 2025) open!!!
To: <info@biobrillouin.org>
Dear All,
It is a pleasure to announce the opening of abstract submissions for the 9th International BioBrillouin Meeting (BioBrillouin 2025) that will take place at the Max Planck Society Conference House in Berlin, Germany on the 25-27th November 2025.
All information pertaining to submission of abstracts and the meeting can be found at:
Deadline for abstract submission is 1st October 2025, with notification of acceptance on 14th October.
Submission for both talks (12min+3min questions) and/or Posters are accepted.
We have assembled an impressive lineup of invited/keynote speakers, that we believe encompass the latest developments in the field (from technology development, interpretations to applications) and provide perspectives/insights for expanding its horizons to new applications of interest to the community. The meeting venue will be the Max Planck Conference House, an intimate setting where many great meetings have taken place over the last century, and promises to provide the perfect opportunity for discussing and building ideas, and networking.
Registration will open shortly (if you submit an abstract we will inform you as soon as it opens, but you will also receive information via this mailing list when it opens). Covered in the registration are all meals (lunches and dinners, including conference banquet) during the course of the meeting.
Please spread the word (friends, colleagues, mailing-lists, end-of-talk announcements, etc.), and we hope to see many of you in Berlin!!
-Kareem
On behalf of the Scientific Organizing Committee:
Jochen Guck - Local Conference Chair (Max Planck Inst. for the Science of Light & MPZ für Physik und Medizin, Germany)
Kareem Elsayad (Medical University of Vienna, Austria)
Robert Prevedel (European Molecular Biology Laboratory - EMBL, Germany)
Francesca Palombo (Exeter University, United Kingdom)
Stephanie Möllmert (Max Planck Institute for the Science of Light, Germany)
Michael Monaghan (Trinity College Dublin, Ireland)
Thorsten Hamann (Norwegian University of Science and Technology, Norway)
Questions pertaining to the meeting should be addressed to: SOC25@biobrillouin.org
PS. This is the same BioBrillouin 2025 meeting that was originally planned to take place in Boston in November 2025, but has been relocated to Berlin.
There will also be a post on social media channels (X, BlueSky, LinkedIn) shortly by @BioBrillouinSoc announcing opening of abstract submissions. If you are active on any of these please forward, like, re-post, or whatever the correct phrase is. Thanks!
_______________________________________________
Info mailing list -- info@biobrillouin.org
To unsubscribe send an email to info-leave@biobrillouin.orgThe information contained in this e-mail message may be privileged, confidential, and/or protected from disclosure. This e-mail message may contain protected health information (PHI); dissemination of PHI should comply with applicable federal and state laws. If you are not the intended recipient, or an authorized representative of the intended recipient, any further review, disclosure, use, dissemination, distribution, or copying of this message or any attachment (or the information contained therein) is strictly prohibited. If you think that you have received this e-mail message in error, please notify the sender by return e-mail and delete all references to it and its contents from your systems.
_______________________________________________Soc25 mailing list -- soc25@biobrillouin.orgTo unsubscribe send an email to soc25-leave@biobrillouin.org
--
Thorsten Hamann